Clinical Trial Update: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine [Phase 3]

View source ↗

Summary

Phase 3 immunogenicity and safety study of GSK's 10-valent pneumococcal conjugate vaccine has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infections Streptococcal

Drugs mentioned

• Pneumococcal conjugate vaccine (pneumococcal conjugate vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Streptococcal | Phase 3 | Status: COMPLETED | Results posted: 2019-01-15